Tofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris—A Case Report
ABSTRACT Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder that can severely impact the quality of life in patients, particularly when presenting in chronic or refractory form. Emerging evidence suggests that JAK inhibitors may offer a potential treatment option. Here, we present a...
| Published in: | Clinical Case Reports |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-10-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.71232 |